Affiliation:
1. GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, India.
Abstract
Rilpivirine is a new second-generation non-nucleoside reverse transcriptase inhibitor used as an anti-viral drug. A new stability indicating reverse phase ultrafast liquid chromatographic method was developed for the assay of Rilpivirine in tablet dosage forms. A Shimadzu UFLC system equipped with Phenomenex C8 column and PDA detector was employed for the chromatographic study. Mobile phase mixture consisting of 10 mM tetra butyl ammonium hydrogen sulphate: Acetonitrile (55: 45) and flow rate 1.0 mL/min (UV detection at 280 nm). Beer-Lambert’s law was obeyed over a concentration range 0.05-40 µg/mL. The linear regression equation was found to be y = 254045x + 11208 (r2 = 0.9999). The LOD and LOQ was found to be and 0.0136 and 0.0414 µg/mL respectively. Stress degradation studies were performed and the method was validated as per ICH guidelines. The proposed method is simple, precise, accurate and robust and can be applied for the quantification of Rilpivirine tablet dosage forms.
Subject
Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference24 articles.
1. Schafer JJ, Short WR. Rilpivirine-a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review. AntivirTher. 2012; 17(8): 1495- 502.
2. Fernandez-Montero JV, Vispo E, Anta L, de Mendoza C, Soriano V. Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. Expert Opin Pharmacother. 2012; 13(7): 1007-1014.
3. Weiss J and Haefeli WE. Potential of the novel antiretroviral drug Rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents. 2013; 41(5): 484-487.
4. Baert L, van 't Klooster G, Dries W, François M, Wouters A, Basstanie E, Iterbeke K, Stappers F, Stevens P, Schueller L, Van Remoortere P, Kraus G, Wigerinck P, Rosier J. Development of a long-acting injectable formulation with nanoparticles of Rilpivirine (TMC278) for HIV treatment. European Journal of Pharmaceutics and Biopharmaceutics. 2009; 72(3): 502-508.
5. Masthanamma Sk and Alekhya G. Development and validation of UV spectrophotometric methods for estimation of Rilpivirine in bulk and pharmaceutical formulation. International Journal of Pharmaceutical Sciences and Research. 2014; 5(2): 483-489.